Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 26 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3Tnb2Z2dmO2aX;uJGF{e2G7 MUGwMlXDqM7:TR?= NUnvfYdKOjRiaB?= NFLlTmF4[XSnch?= NHPoelFud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MX6yOVEzOzB6Mh?=
Eca109 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jIVFAvPS9{LkWvOUDPxE1? M4i0e|I1NzR6L{eyJIg> MlLte4F1\XJ? NVWwVVV3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M4XJWlI2OTJ|MEiy
Eca109 M1zrdmZ2dmO2aX;uJGF{e2G7 MWGwMlXDqM7:TR?= MkfWOk8yOi9{NDDo NF3kbYh4[XSnch?= MUXpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi Mm\SNlUyOjNyOEK=
Eca109 MoPUSpVv[3Srb36gRZN{[Xl? MViwMlXDqM7:TR?= MmfiNlQhcA>? MX73ZZRmeg>? MXPpcohq[mm2czDj[YxtKGmwdnHzbY9v M2j6dFI2OTJ|MEiy
Eca109 NYjndm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT3flgyOC53wrFOwG0> Mln0NlQhcA>? NYrvPYZHf2G2ZYK= M3foWIlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MlXzNlUyOjNyOEK=
Eca109 M3TWfWZ2dmO2aX;uJGF{e2G7 MkTqNE42NzFizszN MlzhNlQhcA>? MXP3ZZRmeg>? NWjiUI9l\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= MlHZNlUyOjNyOEK=
SW1116  MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;WNE42NzFxMj:1JO69VQ>? NIDDRmY1QCCq NXLLWmdDTE2VTx?= NVO1fo92\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M4XuclI1QDd2Mki2
LOVO NVvydVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jXVlAvPS9zL{KvOUDPxE1? MknBOFghcA>? NWizc2xETE2VTx?= NFPHUGRmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NXrFflhWOjR6N{SyPFY>
SW1116  MVPGeY5kfGmxbjDBd5NigQ>? M1j2bFExKM7:TR?= MVu0PEBp NY\JVXZzTE2VTx?= NVzu[Yl[cW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NH7z[HgzPDh5NEK4Oi=>
LOVO Mlq5SpVv[3Srb36gRZN{[Xl? MoK4NVAh|ryP MYm0PEBp Mke1SG1UVw>? MoT6bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MojYNlQ5PzR{OE[=
SW1116  NFnnXYhCeG:ydH;zbZMhSXO|YYm= MVixNEDPxE1? M2XCZ|Q5KGh? MUPEUXNQ NGLESpBmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M1XXc|I1QDd2Mki2
LOVO NEPsNXZCeG:ydH;zbZMhSXO|YYm= MXOxNEDPxE1? NG[yXXQ1QCCq NXTTSoJkTE2VTx?= MX7lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= M{fnclI1QDd2Mki2
RPMI-8226 Mn3lRZBweHSxc3nzJGF{e2G7 MUSxM|Ih|ryP M1L3WFQ5Nzd{L{m2JIg> MlzqSG1UVw>? M{nWNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MknJNlQ5OzNzMEi=
OPM-2  MVnBdI9xfG:|aYOgRZN{[Xl? NH\xdJQyNzJizszN M1i0[FczNzl4L{GyNEBp NV\mN5RLTE2VTx?= NEDMUW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnS0NlQ5OzNzMEi=
JJN3  MkXsRZBweHSxc3nzJGF{e2G7 NF7JW|cxNjVxMTFOwG0> M2XpdFI1NzR6IHi= NHX4OI1FVVOR M{LqTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnjrNlQ5OzNzMEi=
NCI-H929  MoXzRZBweHSxc3nzJGF{e2G7 MYOxM|Ih|ryP MYS3Nk86Pi9zMkCgbC=> MWDEUXNQ MW\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmfvNlQ5OzNzMEi=
RPMI-8226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[zUVh7OS9{IN88US=> MljDNlQwPDhxN{KgbC=> NF;tUnZFVVOR MVLh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NYf0RoFIOjR6M{OxNFg>
OPM-2  NFfLdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f0c|EwOiEQvF2= NIr2cpUzPC92OD:3NkBp M3LXWmROW09? M{LsRoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MX2yOFg{OzFyOB?=
JJN3  Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;iNE42NzFizszN MYiyOE81QC95MjDo NGjQZ|RFVVOR NVjqb5VL[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NXTjRYE{OjR6M{OxNFg>
NCI-H929  MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHLXZgyNzJizszN MVqyOE81QC95MjDo MV7EUXNQ M4jxcoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NWjqToI5OjR6M{OxNFg>
HeLa M2O1ZWtqdmG|ZTDBd5NigQ>? M{HtemtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> NEnW[5AzPDd6MEC5PC=>
HeLa NV\lNXJrU2mwYYPlJGF{e2G7 NVHq[WtoU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MW[yOFc5ODB7OB?=
HeLa Moi3T4lv[XOnIFHzd4F6 MkX2T4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NIHkNGwzPDd6MEC5PC=>
HeLa NFvnfmpMcW6jc3WgRZN{[Xl? NXu0Z296U2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? Ml[4NlQ4QDByOUi=
NB4 NGnHTpVHfW6ldHnvckBCe3OjeR?= NFfRVIMzNjVxNT:3MlUwOTBizszN NGLtT5UzPCCq MknzSG1UVw>? NYrkRVc6cW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NVLSVolmOjR2OES4O|A>
CD4+ CD25− T  Mn3hSpVv[3Srb36gRZN{[Xl? NUftenJQOS93IN88US=> M2C5UpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NEnNS5MzPDR5NkO2NC=>
BV-173 MVfBdI9xfG:|aYOgRZN{[Xl? NUH4Npc6OC5{NT:wMlUwOC55NT:xJO69VQ>? NH36bo41QC95Mj:5OkBp NIjIcHDDqFCEUx?= NYX1OmwzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MY[yOFQzOzZzMx?=
ML-1 MX;BdI9xfG:|aYOgRZN{[Xl? MX6wMlI2NzBwNT:wMlc2NzFizszN NGL0XlM1QC95Mj:5OkBp NVO4UJh6yqCSQmO= MUDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MoLwNlQ1OjN4MUO=
HL-60 NX3VPWg3SXCxcITvd4l{KEG|c3H5 NE\FdIsxNjJ3L{CuOU8xNjd3L{Gg{txO MoDCOFgwPzJxOU[gbC=> NV;scG9qyqCSQmO= NVOzRXhycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NU\WblVnOjR2MkO2NVM>
KG-1a NULIR45RSXCxcITvd4l{KEG|c3H5 NV2xTHhXOC5{NT:wMlUwOC55NT:xJO69VQ>? M1XwNlQ5Nzd{L{m2JIg> NG\Nd23DqFCEUx?= MlPIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MX:yOFQzOzZzMx?=
BV-173 M4q5WGZ2dmO2aX;uJGF{e2G7 MVmyOVAwPTBybl2= MX20PEBp NVTacnlmyqCSQmO= MkLJbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NEnnUmozPDR{M{[xNy=>
CEM MWjGeY5kfGmxbjDBd5NigQ>? M3TV[VI2OC93MEDuUS=> NX3Rc4w{PDhiaB?= MXhCpHBDWw>? M2HkfIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MWiyOFQzOzZzMx?=
HL-60 MnjFSpVv[3Srb36gRZN{[Xl? M1\EOVI2OC93MEDuUS=> MXS0PEBp MmTJxsBRSlN? MVfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NHjB[IMzPDR{M{[xNy=>
ML-1 NV3l[HgxTnWwY4Tpc44hSXO|YYm= MWSyOVAwPTBybl2= MmHQOFghcA>? Mn;5xsBRSlN? M1S0d4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M3f6WVI1PDJ|NkGz
DLD-1 MkfJSpVv[3Srb36gRZN{[Xl? Mn;INlUxNzVyMH7N M3X2fFQ5KGh? NXXWbHhsyqCSQmO= MWPkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NITJUmczPDR{M{[xNy=>
HCT-116 MVLGeY5kfGmxbjDBd5NigQ>? MmK3NlUxNzVyMH7N Moi5OFghcA>? M2PVUuKhWEKV MmrJ[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MVmyOFQzOzZzMx?=
U937-A/E-9/14/18  MnLWRZBweHSxc3nzJGF{e2G7 MkHPNE4xOS9yLkGvNU8yOCEQvF2= NITmcoI1QCCq NXXoUIpEcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF\CbFczPDNyMES1Oi=>
HT29 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNXpg4OiCq MYjJR|UxRTF2MEFCtVE4QSEQvF2= MlvBNlQyPzJyNkG=
SW48 NHHaRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3O|IhcA>? MmiwTWM2OD1zNT6yxtE3NjJizszN M4jQSlI1OTd{ME[x
HCT116 NWLTfJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm1O|IhcA>? MoHJTWM2OD1zLkhCtVAvPCEQvF2= M4SydVI1OTd{ME[x
HepG2 M3vEcWZ2dmO2aX;uJGF{e2G7 M{m5elAvPS9zIN88US=> NV76SoZbOjRiaB?= NWjSZYU3TE2VTx?= MV71dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? NHrMRXkzPDF2Nki3OC=>
LS174T NHXV[pBHfW6ldHnvckBCe3OjeR?= NVfYe4NtOC53L{Gg{txO NE\HeVAzPCCq MXfEUXNQ MkLycIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= MXKyOFE1Pjh5NB?=
HepG2 MorqRZBweHSxc3nzJGF{e2G7 MWmxM|ExNzFyMDFOwG0> MWe3JIQ> MmLlSG1UVw>? MljYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF65OZUzPDF2Nki3OC=>
LS174T Mon5RZBweHSxc3nzJGF{e2G7 NV\LWJY4OS9zMD:xNFAh|ryP MlPIO{Bl NGHhcZpFVVOR NWHTTodTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2DtdVI1OTR4OEe0
QBC-939 NHrOOoxCeG:ydH;zbZMhSXO|YYm= NYfGbHFUOS9zMD:xNFAh|ryP M1\KRlch\A>? MomzSG1UVw>? NVPXdHdscW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXeyOFE1Pjh5NB?=
U251 NWn4[pZMSXCxcITvd4l{KEG|c3H5 MWCxM|ExNzFyMDFOwG0> MmP6O{Bl NVXrbWhOTE2VTx?= MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmfNNlQyPDZ6N{S=
HL-60 NHzEboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xJO69VQ>? NIn6fow1QCCq NWjpXYZOcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= NVrpWJM5OjRyMECzNlQ>
MDA‑MB‑453 NEjleIVHfW6ldHnvckBCe3OjeR?= M{Kyd|AvOi9zIN88US=> MYW3NkBp M4j0coNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M1rPOVI{QDR2MkK4
HCC1569 NHjISZBHfW6ldHnvckBCe3OjeR?= NECxRXIxNjJxMTFOwG0> MUW3NkBp M2LEXoNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MoG3NlM5PDR{Mki=
BT‑474 Mn7LSpVv[3Srb36gRZN{[Xl? M{TpfVAvOi9zIN88US=> MlLUO|IhcA>? MnO2Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NWjGVXhqOjN6NESyNlg>
AGS MnHYRZBweHSxc3nzJGF{e2G7 MojtOU8yOC9{MD:1NEDPxE1? MV20POKhcMLi NU[3XXhZTE2VTx?= MkfhbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> M3j6dlI{PTh{N{i0
A549 NWfQdZZwSXCxcITvd4l{KEG|c3H5 Mk[xOU8yOC9{MD:1NEDPxE1? NXv3RYU3PDkEoHlCpC=> MkHkSG1UVw>? NYHvOFhzcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NXr0VphVOjN3OEK3PFQ>
AGS  MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG1M|ExNzJyL{WwJO69VQ>? NYTiUGJJPDkEoHlCpC=> M2\DUmROW09? MnLrbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MWKyN|U5Ojd6NB?=
Kasumi-1 NYXOT25GSXCxcITvd4l{KEG|c3H5 NFX4doYxNjVizszN NXrqZmZKPDkEoHlCpC=> MX7k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M3mz[FI{PDl|M{S4
OCI-AML3 NVHETIIxSXCxcITvd4l{KEG|c3H5 NFric2UzNjVizszN MoL1OFjDqGkEoB?= MnrO[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NHLHd2ozOzR7M{O0PC=>
MV4-11 NH;6[ZVCeG:ydH;zbZMhSXO|YYm= MmPLNk42KM7:TR?= M3juO|Q5yqCqwrC= MnOy[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M{PYfFI{PDl|M{S4
NK  M{W2OmN6fG:2b4jpeJkhSXO|YYm= NVnJbIZGOC5yMj2yNEDPxE1? MlrPOUBl NXzBWHN7\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= Mk\ENlM{OjhyOEi=
NK  NGfhUVdCeG:ydH;zbZMhSXO|YYm= NID2bWYxNjB{LUKwJO69VQ>? M2DqR|Uh\A>? NXXpUWhn\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm Mm\BNlM{OjhyOEi=
NK  NGD4UXVHfW6ldHnvckBCe3OjeR?= Mom3NE4xOS1{MDFOwG0> NVXGWXNKPSCm MoGwZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> M{jFOFI{OzJ6MEi4
MOLT4/DNR Mm\mSpVv[3Srb36gRZN{[Xl? NVvwTmdwPSEQvF2= MnTzOEBl MXPy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NUTLdGl2OjNyNkC1O|A>
Jurkat/DOX NXi3SFdmTnWwY4Tpc44hSXO|YYm= MX21JO69VQ>? NV22cmJyPCCm NEXp[mlz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MmnTNlMxPjB3N{C=
MOLT4/DNR MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn2bmk2KM7:TR?= MXm0JIQ> NXTtdZA4emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M2D4NVI{ODZyNUew
Jurkat/DOX MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPUOUDPxE1? MojMOEBl NYX3R3VVemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M3LHTVI{ODZyNUew
ccRCC  M2\HNmFxd3C2b4Ppd{BCe3OjeR?= M1i5b|AvODFvMUFOwG0> M1nhelczKGh? NHzXcJNFVVOR MVPoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MVWyNlgzPjR4Nx?=
TNBC  NH3aU49CeG:ydH;zbZMhSXO|YYm= NVPvTm1DOC5yMT2xNO69VQ>? MlrWO|IhcA>? MXHEUXNQ MljNbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MVKyNlgzPjR4Nx?=
A498 NHf5RlFCeG:ydH;zbZMhSXO|YYm= MUGwMlAyNTFyzszN NFOwO4Y4OiCq NFHzXm9FVVOR MnHUbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M2fSVlIzQDJ4NE[3
KIJ265T MoK1RZBweHSxc3nzJGF{e2G7 MnyzNE4xOS1zMN88US=> Mk\zO|IhcA>? MUTEUXNQ NUj0NZdkcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NUjHWIZqOjJ6Mk[0Olc>
MDA-231 MXzBdI9xfG:|aYOgRZN{[Xl? NYT6bGVYOC5yMT2xNO69VQ>? M3;HPFczKGh? MXzEUXNQ NGTxeWJqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MWmyNlgzPjR4Nx?=
BT-20 Moj5RZBweHSxc3nzJGF{e2G7 NVj6dVl1OC5yMT2xNO69VQ>? NID4dVk4OiCq MVjEUXNQ M2jVRYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NWPFPHh{OjJ6Mk[0Olc>
U937 NV7C[XV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjTZNLPS1{MDFOwG0> MX:yOE81QC95MjDo NITBRoNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NUnEW|FNOjJ5NkewNlE>
HL60 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LXUVUuOjBizszN MVOyOE81QC95MjDo MonKbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MlzRNlI4PjdyMkG=
U937 Mn;hRZBweHSxc3nzJGF{e2G7 MWGxOUDPxE1? MXiyOE81QC95MjDo MljhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{i3XVIzPzZ5MEKx
HL60 M3L2d2Fxd3C2b4Ppd{BCe3OjeR?= MVOxOUDPxE1? NGnMWIkzPC92OD:3NkBp MV3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3uxN|IzPzZ5MEKx
LS411N  NXzxcFZ4SXCxcITvd4l{KEG|c3H5 NXTz[nZbOC53IN88US=> MYC3NkBp NWjpbFJjcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs M{XSXVIzPDZzNkm1
MDA-MB-231 MlztRZBweHSxc3nzJGF{e2G7 MU[xNEDPxE1? NULvfYhpPDhiaB?= MnTFdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlG2NlE5QDd4OUe=
MCF-7  M4jPPGFxd3C2b4Ppd{BCe3OjeR?= NY[zZ3E5OTBizszN NHXqR2s1QCCq NXrM[YF1emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlPMNlE5QDd4OUe=
A375 NUO4Z5Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPjdXFROC53IN88US=> NYHD[|JDOS93L{ig[C=> NYfsOpRTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MnPpNlE4QTZ4MkK=
SKMEL1 NHi2bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUewMlUh|ryP MoHiNU82NzhiZB?= NUjTSFhxcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MknFNlE4QTZ4MkK=
SKMEL3 M1LmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOxbWNzOC53IN88US=> NXrRUWp4OS93L{ig[C=> M2Lab4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NGXNdZYzOTd7Nk[yNi=>
SKMEL28 NFjTe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLmc2wxNjVizszN MUSxM|UwQCCm M{jPR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MXSyNVc6PjZ{Mh?=
MeWo NHq2VmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:3cVAvPSEQvF2= Moe5NU82NzhiZB?= MkTNbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MoDnNlE4QTZ4MkK=
B16 NHv6cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3OWdwOC53IN88US=> MWSxM|UwQCCm M1LYVolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M{jBSVIyPzl4NkKy
Ly 1 NITrT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr5N5MzPCCq M3\ud2lEPTB;Nz6zJO69VQ>? M1zsU|IyPzd{MES5
Ly 7 NWO3dGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiyOEBp NWL3dZBqUUN3ME2xNE44KM7:TR?= M124blIyPzd{MES5
Su-DHL6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\RNlQhcA>? M{S1[2lEPTExvK6yNEDPxE1? MlXoNlE4PzJyNEm=
Ly 10 NHzvfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf2e3VDOjRiaB?= MU\JR|Ux97zgMkCg{txO MWWyNVc4OjB2OR?=
RIVA M3\C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:yOEBp MkHSTWM2OO,:nkKwJO69VQ>? MlfZNlE4PzJyNEm=
Su-DHL2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPaNlQhcA>? MXnJR|Ux97zgMkCg{txO M3:wTlIyPzd{MES5
Ly 1 NVnpRlRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDZOFghcA>? M2jpXmlEPTB;MD6zOEDPxE1? Mnj5NlE4PzJyNEm=
Ly 7 NX72S3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLpelQ1QCCq Ml7XTWM2OD1yLkCyOUDPxE1? MnjaNlE4PzJyNEm=
Su-DHL6 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriOFghcA>? MmjBTWM2OO,:nkKwJO69VQ>? MVyyNVc4OjB2OR?=
Ly 10 M2\teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi0PEBp NF;OdmFKSzVyPUGuPEDPxE1? M2fpVVIyPzd{MES5
RIVA Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPpOFghcA>? NWrzV2s{UUN3MP-8olIxKM7:TR?= NWflVHV6OjF5N{KwOFk>
Su-DHL2 M2njU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;qOFghcA>? MYrJR|UxRTF5LkSg{txO M3jWV|IyPzd{MES5
Ly 1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp NGHZN2xKSzVyPUCuNFEh|ryP NIHINHozOTd5MkC0PS=>
Ly 7 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:0O|IhcA>? NWX1UYFCUUN3ME2wMlAyQCEQvF2= NXTBV5ZwOjF5N{KwOFk>
Su-DHL6 NGPWdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXLTGM4OiCq MVvJR|UxRTFwNjFOwG0> MmLiNlE4PzJyNEm=
Ly 10 NXXC[2VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pO|IhcA>? NFLpcpZKSzVyPUGuNkDPxE1? NITTUYIzOTd5MkC0PS=>
RIVA MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWK3NkBp M3LlT2lEPTExvK6yNEDPxE1? MXeyNVc4OjB2OR?=
Su-DHL2 M4fuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjQWlQ4OiCq NYLRUJZZUUN3ME2xNU4zKM7:TR?= NIr3VIwzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID